VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
REGN
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
REGNRegeneron Pharmaceuticals, Inc.
$957.76$98.7B
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
REGN logo

Regeneron Pharmaceuticals, Inc.

REGN
NASDAQ · Immunology Biotech
$957.76
At close - Nov 17, 4:00 PM EST - USD
Market Cap$98.67B
P/E21.0x
52W High$991.73
Volume927.33K
OverviewTerminalAnalysisFinancialsValuationEarningsBreakoutsOwnership
VCP Research Verdict2026Q3

Lumpy Earnings Recovery Meets Strong Balance Sheet Discipline

Regeneron's latest quarter shows sharp acceleration, with revenue up 36.3% year-over-year to $5.1B and gross margin expanding to 88.8%, suggesting operating leverage may be taking hold after a choppy 2025 to early 2026.

GrowthMixed
ProfitabilityModerate
ValuationAttractive
TechnicalsStrong
Explore valuation models
MARKET ACTION

REGN price & volume

Price trend, volume and key moving averages

Launch Terminal
Loading chart...
Decision Checklist4 Core Signals

What matters now

The signals most likely to change the investment case.

01

Earnings momentum

10/12 Beats

EPS beat 10 of last 12 quarters

02

Valuation risk

-45% Peers

P/E is 45% below peer median

03

Market leadership

RS 89 · Leader

High momentum (Outperforming 89% of market)

04

Strong Uptrend

Strong Trend

Price > 20DMA > 50DMA > 200DMA

Next CatalystEstimated earnings · Jan 30
01

Build the investment case

Start with the evidence for owning the stock and the risks that can break the thesis.

EXECUTIVE THESIS

The Investment Case

Full Analysis
Fundamental Trajectory

Revenue and margins have trended sharply higher in the latest quarter, with gross margin reaching 88.8% and operating margin 40.0% in 2026Q3, although prior quarters showed uneven growth of 16.7% and 19.0%, suggesting the improvement may be lumpy rather than steady.

Analyst Consensus-5.6% target
Buy(49 analysts)
34 Buy15 Hold0 Sell

The Bull Case

Upside Catalysts

Strong product pipeline

Regeneron focuses on discovering and developing medicines for serious medical conditions, indicating a robust pipeline of potential treatments.

Investor relations focus

The company maintains a dedicated Investor Relations website, showcasing transparency and engagement with stockholders and analysts.

Biotechnology leadership

As a long-standing biotech firm since 1988, Regeneron has established expertise in developing and commercializing innovative therapies.

The Bear Case

Key Downside Risks

Market performance

Price History →

Trailing total returns as of 11/18/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).

YTD Return
REGN+23.74%
S&P 500 (^GSPC)+7.21%
1-Year Return
REGN+36.51%
S&P 500 (^GSPC)+10.03%
3-Year Return
REGN+20.15%
S&P 500 (^GSPC)+62.22%
5-Year Return
REGN+50.21%
S&P 500 (^GSPC)+57.55%
02

Test the fundamentals

Check whether operating performance supports the current valuation.

VALUATION & INTRINSIC VALUE

Valuation Scenarios

Valuation Analysis
Trailing P/E5Y High
21.0x
Forward P/EExpansion
14.1x
EV/EBITDA40th %ile
17.9x
FCF YieldCash Flow
3.6%

Valuation vs 5-Year History

Multiple Range
Metric
Current
5Y Median
Historical Range
Percentile
P/E
21.0x
18.6x
80th· High
EV/EBITDA
17.9x
18.4x
40th· Fair
Price/FCF
27.5x
20.5x
100th· High
Current Multiple
5Y Median (50th %ile)

Intrinsic Value Scenarios

DCF Projection
Bear$676.47-29.4%
Base (Fair)$1050.52+9.9%
Bull$1635.64+70.8%
$676.47 Bear$1050.52 Base$1635.64 Bull
Current Market Price: $957.76
Trades at a 8.8% discount to Base DCF ($1050.52)
Open DCF & Valuation Models →Chart Terminal ↗

Growth & profitability

Annual revenue & EPS trend
Revenue FY25
$14.34B+1.0% YoY
Net income FY25
$4.5B+2.1% YoY
Free cash flow FY25
$4.08B+11.3% YoY
Operating margin FY25
24.9%-3.2 pts YoY
ROIC (FY25)8.9%
Avg ROIC 5Y19.5%
ROE (TTM)15.1%
Piotroski Score5 / 9
Financial Statements →
03

Monitor what changed

Recent results and news deserve attention only when they alter the forward view.

OPERATING RESULTS

Recent Earnings

Earnings History
EPS Beat Rate10/12 (83%)
Revenue Beat Rate10/12 (83%)
QuarterEPS (Act vs Est)Revenue (Act vs Est)
Q4 2026Latest
Oct 30, 2026
$20.07+21.6%
vs $16.51
$5.1B+11.6%
vs $4.6B
Q3 2026
Jul 30, 2026
$14.29+40.6%
vs $10.16
$4.3B+12.4%
vs $3.8B
Q2 2026
Apr 29, 2026
$9.47+6.3%
vs $8.91
$3.6B+3.6%
vs $3.5B
Q1 2026
Jan 30, 2026
$11.44+6.5%
vs $10.74
$3.9B+1.9%
vs $3.8B
Historical baseline: 12 quarters analyzedGAAP / Adjusted
MARKET COVERAGE

Latest News

4 Stories
MarketBeat·22h ago
Regeneron Pharmaceuticals Sees Growth Ahead, Eyes EYLEA HD Syringe Approval

Regeneron Pharmaceuticals NASDAQ: REGN expects its three largest growth drivers to continue supporting revenue growth, while planning higher research and development spending and preparing for a specialty drug launch, executives said at the Jefferies Healthcare Conference.

Seeking Alpha·23h ago
Regeneron Pharmaceuticals, Inc. (REGN) Presents at Jefferies Global Healthcare Conference 2026 Transcript

Regeneron Pharmaceuticals, Inc. (REGN) Presents at Jefferies Global Healthcare Conference 2026 Transcript

Defense World·1d ago
Regeneron Pharmaceuticals, Inc. $REGN Position Lifted by Banco Santander S.A.

Banco Santander S.A. boosted its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) by 6.4% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 54,756 shares of the biopharmaceutical company's stock after purchasing an additional 3,277 shares during the quarter.

Defense World·1d ago
Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by AlTi Global Inc.

AlTi Global Inc. decreased its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) by 75.2% in the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 463 shares of the biopharmaceutical company's stock after selling 1,401 shares during the quarter. AlTi Global Inc.'s holdings

Filtered for Regeneron Pharmaceuticals, Inc.More Headlines
04

Compare before deciding

Benchmark REGN against direct peers instead of judging its metrics in isolation.

Peers Comparison

Key metrics vs top competitors for Regeneron Pharmaceuticals, Inc. (REGN)

Full Screener →
CompanyPriceMarket CapP/E RatioRev Growth (1Y)Net MarginROEDiv Yield
REGN logoREGNRegeneron Pharmaceuticals, Inc.Current
$957.76$98.67B20.990.99%28.51%15.07%0.36%
BIIB logoBIIBBiogen Inc.
$250.79$37.06B106.521.39%3.38%1.86%—
VRTX logoVRTXVertex Pharmaceuticals Incorporated
$534.20$135.58B34.299.57%30.61%20.08%—
INCY logoINCYIncyte Corporation
$119.09$24.14B60.0021.22%6.71%7.11%—
BMRN logoBMRNBioMarin Pharmaceutical Inc.
$58.51$11.31B-592.8112.87%-0.52%-0.31%—
ABBV logoABBVAbbVie Inc.
$292.86$517.42B50.148.57%15.68%—2.24%

Compare REGN vs Peers

Regeneron Pharmaceuticals, Inc. (REGN) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs BIIB

Most directly comparable listed peer for REGN.

Scale Benchmark

vs LLY

Larger-name benchmark to compare REGN against a more recognizable public peer.

Peer Set

Compare Top 5

vs BIIB, VRTX, INCY, BMRN

05

Keep researching

Verify the primary filings, follow material updates, and answer the remaining questions.

REGN SEC Filings & Documents

Regeneron Pharmaceuticals, Inc. (REGN) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

6
Material company update

Oct 30, 2026·SEC

Material company update

Oct 6, 2026·SEC

Material company update

Jul 30, 2026·SEC

10-K Annual Reports

3
FY 2026

Feb 4, 2026·SEC

FY 2025

Feb 5, 2025·SEC

FY 2024

Feb 5, 2024·SEC

10-Q Quarterly Reports

6
FY 2026

Oct 30, 2026·SEC

FY 2026

Jul 30, 2026·SEC

FY 2026

Apr 29, 2026·SEC

Get notified when REGN posts new earnings or crosses analyst targets

Free. No account needed. Unsubscribe any time.

Free. Unsubscribe any time.

REGN Frequently Asked Questions

Regeneron Pharmaceuticals, Inc. (REGN) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials
What is Regeneron Pharmaceuticals, Inc.'s revenue?

Regeneron Pharmaceuticals, Inc. (REGN) reported $16.90B in revenue over the trailing twelve months. Revenue was $14.34B in fiscal year 2025. That is 59414% more than the $24.1M of fiscal year 1996.

How fast is Regeneron Pharmaceuticals, Inc. growing?

Regeneron Pharmaceuticals, Inc. (REGN) grew revenue by 18.6% over the trailing twelve months, compared with the twelve months before.

Is REGN profitable?

Yes. Regeneron Pharmaceuticals, Inc. (REGN) earned $4.82B in net income over the trailing twelve months (a 28.5% net margin).

Dividend & Returns
Does REGN pay dividends?

Yes. Regeneron Pharmaceuticals, Inc. (REGN) pays a dividend that yields 0.36% at the current price, a small yield.

What is REGN's return on equity?

Regeneron Pharmaceuticals, Inc. (REGN) had a return on equity (ROE) of 15.1% over the trailing twelve months. That is above the market's typical 10-15%.

What is Regeneron Pharmaceuticals, Inc.'s free cash flow?

Regeneron Pharmaceuticals, Inc. (REGN) generated $3.59B in free cash flow over the trailing twelve months.

What if you invested $1,000 in REGN back in 1996?

Total return calculator · dividends reinvested · 30+ years of data

See returns →